Overview

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central nervous system stimulant that can improve cognitive ability, mainly in memory and cognitive function. Exercise can improve mood and the physical aspects of cancer-related fatigue. Giving methylphenidate in combination with exercise may work better in reducing cancer-related fatigue in patients with prostate cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Methylphenidate